Here’s Why uniQure (QURE) Declined in Q4

2 days ago 3

Attiya Zainib

Mon, February 2, 2026 astatine 8:35 AM CST 3 min read

Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. Apis Flagship Fund delivered beardown show successful the 4th fourth of 2025, with the Fund up 10.0% nett for the 4th and gaining 55.1% for the afloat year, importantly outperforming the MSCI ACWI planetary benchmark by astir 7.0% successful Q4 and 33.0% for the year. Long positions drove the bulk of gains arsenic they generated 11.9% gross contribution, portion shorts added a further 0.8% gross, with the portfolio positioned astir 68% nett agelong arsenic of December. Performance was broad-based, arsenic Technology and Healthcare led quarterly returns, and beardown contributions besides came from basal materials, portion small-capitalization stocks narrowed their accepted underperformance comparative to ample caps. Looking ahead, the steadfast highlighted its continued accent connected bottom-up banal selection, structural exposures to niche opportunities crossed healthcare, semiconductors, and industrials, and the persistent attractiveness of non-U.S. markets arsenic cardinal drivers for aboriginal imaginable returns. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its fourth-quarter 2025 capitalist letter, Apis Capital Advisors highlighted stocks similar uniQure (NASDAQ:QURE).uniQure (NASDAQ:QURE) is simply a cistron therapy institution focused connected processing one-time treatments for uncommon and neurological diseases utilizing its proprietary AAV-based transportation technology. The one-month instrumentality of uniQure (NASDAQ:QURE) was 0.44% portion its shares traded betwixt $7.76 and $71.50 implicit the past 52 weeks. On January 30, 2026, uniQure (NASDAQ:QURE) banal closed astatine astir $22.72 per share, with a marketplace capitalization of astir $1.4 billion.

Apis Capital Advisors’ Apis Flagship Fund stated the pursuing regarding uniQure (NASDAQ:QURE) successful its Q4 2025 capitalist letter:

"uniQure (NASDAQ:QURE) detracted astir 1.1%, portion respective of our Korean defense-related holdings collectively detracted astir 2.5% successful Q4. We property this weakness to a method intermission pursuing beardown anterior show alternatively than immoderate deterioration successful fundamentals."

uniQure (QURE) Navigates Gene Therapy Development arsenic Investors Weigh Long-Term Potential

LightField Studios/Shutterstock.com

uniQure (NASDAQ:QURE) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 59 hedge money portfolios held uniQure (NASDAQ:QURE) astatine the extremity of the 3rd quarter, which was 36 successful the erstwhile quarter. While we admit the hazard and imaginable of uniQure (NASDAQ:QURE) arsenic an investment, our condemnation lies successful the content that immoderate AI stocks clasp greater committedness for delivering higher returns and doing truthful wrong a shorter clip frame. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.